Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen
Research output: Contribution to journal › Article › peer-review
44Scopus
citations
Fingerprint
Dive into the research topics of 'Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen'. Together they form a unique fingerprint.